Chemed Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
ChemedDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -0.6% zurückgegangen, während in der Branche Healthcare die Gewinne wachsen. Die Umsatzerlöse sind gewachsen mit einer durchschnittlichen Rate von 4.4% pro Jahr. Chemed Die Eigenkapitalrendite des Unternehmens beträgt 30.6%, und die Nettomargen liegen bei 10.2%.
Wichtige Informationen
-0.55%
Wachstumsrate der Gewinne
1.26%
EPS-Wachstumsrate
| Healthcare Wachstum der Industrie | 8.50% |
| Wachstumsrate der Einnahmen | 4.42% |
| Eigenkapitalrendite | 30.64% |
| Netto-Marge | 10.23% |
| Letzte Ertragsaktualisierung | 31 Mar 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).
Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy
Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking AlphaNew Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.Chemed Corporation (NYSE:CHE) Shares Could Be 23% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$614 Chemed's US$473 share...
Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward
Strategic acquisitions, such as Covenant Health, and aggressive hiring in VITAS are poised to enhance Chemed's revenue and net margins through improved operational efficiency.Chemed Remains A Buy On Long-Term Economics
Summary Chemed continues to present with exceptional economic characteristics now at depressed valuations vs. history. The business is highly profitable and earns high rates of return on all the capital that's been employed into its operations. Management has an extensive reinvestment runway to redeploy surplus funds and grow the intrinsic worth of the business. Read the full article on Seeking AlphaAufschlüsselung der Einnahmen und Ausgaben
Wie Chemed Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 2,541 | 260 | 423 | 0 |
| 31 Dec 25 | 2,530 | 265 | 414 | 0 |
| 30 Sep 25 | 2,531 | 279 | 416 | 0 |
| 30 Jun 25 | 2,512 | 290 | 407 | 0 |
| 31 Mar 25 | 2,489 | 309 | 414 | 0 |
| 31 Dec 24 | 2,431 | 302 | 419 | 0 |
| 30 Sep 24 | 2,377 | 302 | 415 | 0 |
| 30 Jun 24 | 2,336 | 301 | 418 | 0 |
| 31 Mar 24 | 2,293 | 283 | 406 | 0 |
| 31 Dec 23 | 2,264 | 273 | 395 | 0 |
| 30 Sep 23 | 2,225 | 245 | 392 | 0 |
| 30 Jun 23 | 2,187 | 226 | 376 | 0 |
| 31 Mar 23 | 2,165 | 240 | 369 | 0 |
| 31 Dec 22 | 2,135 | 250 | 359 | 0 |
| 30 Sep 22 | 2,129 | 262 | 354 | 0 |
| 30 Jun 22 | 2,141 | 277 | 359 | 0 |
| 31 Mar 22 | 2,142 | 267 | 365 | 0 |
| 31 Dec 21 | 2,139 | 269 | 367 | 0 |
| 30 Sep 21 | 2,132 | 308 | 361 | 0 |
| 30 Jun 21 | 2,121 | 303 | 361 | 0 |
| 31 Mar 21 | 2,091 | 329 | 351 | 0 |
| 31 Dec 20 | 2,080 | 319 | 330 | 0 |
| 30 Sep 20 | 2,069 | 271 | 322 | 0 |
| 30 Jun 20 | 2,021 | 263 | 311 | 0 |
| 31 Mar 20 | 1,992 | 231 | 298 | 0 |
| 31 Dec 19 | 1,939 | 220 | 306 | 0 |
| 30 Sep 19 | 1,874 | 209 | 289 | 0 |
| 30 Jun 19 | 1,837 | 201 | 279 | 0 |
| 31 Mar 19 | 1,806 | 205 | 276 | 0 |
| 31 Dec 18 | 1,783 | 206 | 271 | 0 |
| 30 Sep 18 | 1,753 | 206 | 276 | 0 |
| 30 Jun 18 | 1,727 | 190 | 275 | 0 |
| 31 Mar 18 | 1,700 | 113 | 271 | 0 |
| 31 Dec 17 | 1,667 | 98 | 271 | 0 |
| 30 Sep 17 | 1,642 | 76 | 261 | 0 |
| 30 Jun 17 | 1,617 | 67 | 254 | 0 |
| 31 Mar 17 | 1,592 | 114 | 249 | 0 |
| 31 Dec 16 | 1,577 | 109 | 238 | 0 |
| 30 Sep 16 | 1,572 | 106 | 240 | 0 |
| 30 Jun 16 | 1,566 | 108 | 234 | 0 |
| 31 Mar 16 | 1,557 | 111 | 233 | 0 |
| 31 Dec 15 | 1,543 | 110 | 233 | 0 |
| 30 Sep 15 | 1,524 | 110 | 229 | 0 |
| 30 Jun 15 | 1,496 | 106 | 229 | 0 |
Qualität der Erträge: CHE hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: CHEDie aktuellen Gewinnspannen (10.2%) sind niedriger als im letzten Jahr (12.4%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: CHEDie Erträge des Unternehmens sind in den letzten 5 Jahren um 0.6% pro Jahr zurückgegangen.
Beschleunigtes Wachstum: CHEDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: CHE hatte im vergangenen Jahr ein negatives Gewinnwachstum (-15.9%), was einen Vergleich mit dem Branchendurchschnitt Healthcare (16%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: CHEDie Eigenkapitalrendite des Unternehmens (30.6%) wird als hoch angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/28 16:13 |
| Aktienkurs zum Tagesende | 2026/06/26 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Chemed Corporation wird von 10 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |